MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2848-2852

  Firsov, Alexander A ^a   Vostrov, Sergey N ^a   Shevchenko, Alexander A ^a   Zinner, Stephen H ^b   Cornaglia, Giuseppe ^c   Portnoy, Yury A ^a  

^a Scientific and Technological Centre Lekbiotech   (Russian Federation)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; DRUG EFFECT; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONBIOLOGICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS;

EID: 0031751627     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2848     Document Type: Article

References (20)

1. Bergan, T., and S. B. Thorsteinsson. 1986. Pharmacokinetics and bioavailability of ciprofloxacin, p. 111-121. In H. C. Neu and H. Weuta (ed.), Proceedings of the 1st International Ciprofloxacin Workshop. Current clinical practice series 34. Elsevier Science Publishers B.V. (Excerpta Medica), Amsterdam, The Netherlands.
2. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
3. Drusano, G. L. 1991. Human pharmacodynamics of beta-lactams, aminoglycosides and their combinations. Scand. J. Infect. Dis. 74(Suppl.):235-248.
4. Firsov, A., A. Shevchenko, S. Vostrov, and S. Zinner. 1997. Trovafloxacin vs Ciprofloxacin against Klebsiella pneumoniae in an in vitro dynamic model, abstr. 2205. In Proceedings of the 20th International Congress of Chemotherapy.
5. Firsov, A., S. Vostrov, O. Kononenku, and S. Zinner. 1998. Gatifloxacin versus ciprofloxacin against staphylococci in an in vitro dyna-mic model of infection, abstr. AMR/MID 13, p. 147 In Program and abstracts of the 5th International Conference on the Prevention of Infection.
6. Firsov, A., S. Vostrov, A. Shevchenko, and S. Zinner. 1997. Trovafloxacin vs. Ciprofloxacin against bacteria of similar susceptibility to both drugs: a study with Pseudomonas aeruginosa in an in vitro dynamic model. Clin. Microbiol. Infect. 3(Suppl. 2):85.
7. Firsov, A., S. Vostrov, S. Zinner, O. Kononenko, and A. Shevchenko. 1998. Trovafloxacin versus ciprofloxacin against staphylococci in an in vitro dynamic model, abstr. 82.021, p. 232. In Abstracts of the 8th International Congress on Infectious Diseases.
8. Firsov, A. A., V. M. Chernykh, and S. M. Navashin. 1991. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob. Agents Chemother. 34:1312-1317.
9. Firsov, A. A., A. D. Nazarov, and V. M. Chernykh. 1989. Pharmacokinetic approaches to rational antibiotic therapy, p. 1-228. In Advances in science and engineering, vol. 17. VINITI Publishers, Moscow, Russia. (In Russian.)
10. Firsov, A. A., A. A. Shevchenko, S. N. Vostrov, and S. H. Zinner. 1998. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:657-665.
11. Firsov, A. A., S. N. Vostrov, A. A. Shevchenko, and G. Cornaglia. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287.
12. Forrest, A., D. E. Nix, C. A. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
13. Hoffken, G., H. Lode, C. Prinzing, K. Borner, and P. Koeppe. 1985. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 27:375-379.
14. Mattie, H., W. A. Craig, and J. C. Pechère. 1989. Determinants of efficacy and toxicity of aminoglycosides. J. Antimicrob. Chemother. 24:281-293.
15. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin; a new paradigm for early clinical trials. JAMA 279:125-129.
16. Schentag, J. J. 1991. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand. J. Infect. Dis. 74(Suppl.):218-234.
17. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. Relationships between AUC above MIC and area under the inhibitory curve (AUC/MIC) for cefmenoxime, ciprofloxacin, and tobramycin. DICP-Ann. Pharmaeother. 25:1050-1057.
18. Vogelman, B., S. Gudmundsson, E. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
19. Wise, R., D. Lister, C. A. M. McNulty, D. Griggs, and J. M. Andrews. 1986. The comparative pharmacokinetics of five quinolones. J. Antimicrob. Chemother. 18(Suppl. D):71-81.
20. Zabinski, R. A., K. J. Walker, A. J. Larsson, J. A. Moody, G. W. Kaatz, and J. C. Rotschafer. 1995. Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones. Antimicrob. Agents Chemother. 39:507-512.